This compound serves as a critical intermediate in the synthesis of Ticagrelor, an orally active, reversible P2Y12 receptor antagonist used for the prevention of atherothrombotic events in patients with acute coronary syndrome or a history of myocardial infarction. Its intricate structure features a 3H-[1,2,3]triazolo[4,5-d]pyrimidine core substituted with a propylthio group at position 5 and a (1R,2S)-2-(3,4-difluorophenyl)cyclopropylamino group at position 7, linked to a stereospecifically protected (3aR,4S,6R,6aS)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl moiety bearing a 2-hydroxyethoxy side chain. This specialty chemical is employed in pharmaceutical research and manufacturing to facilitate the production of targeted cardiovascular therapies, with the protecting groups allowing for efficient stereocontrolled synthesis and deprotection to the final drug molecule.